Precision BioSciences, Inc.
Every calculator, already run for DTIL
Open the full toolkit →You have the numbers on DTIL. Get the argument.
A written report on which of these readings actually decide the outcome for Precision BioSciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering DTILAnalyst Price Target Disagreement for Precision BioSciences, Inc.
Wall Street's bull case implies +737% from the current price; the bear case implies +151%. A 586% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for DTIL
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the tre…
DTIL — frequently asked
Is DTIL a buy right now?
Wall Street's consensus rating on Precision BioSciences, Inc. is none across 5 analysts, with a mean price target of $29.40 (+310% vs. the current $7.17). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is DTIL's next earnings date?
Precision BioSciences, Inc. is next scheduled to report earnings around Nov 2, 2026. A full DTIL research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Precision BioSciences, Inc.?
Analysts covering Precision BioSciences, Inc. (DTIL) range from a bear-case target of $18.00 to a bull-case high of $60.00, with a mean consensus target of $29.40 across 5 analysts. The spread of $42.00 (586% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Precision BioSciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Precision BioSciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full DTIL research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Precision BioSciences, Inc., in minutes. 3 free reports included with every account — no credit card required.